Reandy Hearn
Physician Assistant · Sanford, NCNPI 1922563667
Payments from drug & device makers
Across 195 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$966
- Harmony Biosciences LLC$498
- AstraZeneca$426
- Jazz Pharmaceuticals Inc.$346
- Sanofi$297
- Grifols USA, LLC$116
- plus $579 from 14 others
What the payments were for
- Food & beverage$3,09596%
- Education$1334%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $966 |
| Harmony Biosciences LLC | 21 | $498 |
| AstraZeneca | 17 | $426 |
| Jazz Pharmaceuticals Inc. | 11 | $346 |
| Sanofi | 17 | $297 |
| Grifols USA, LLC | 4 | $116 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $71 |
| Boehringer Ingelheim | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Mylan Specialty L.p. | 2 | $56 |
| Inspire Medical Systems, Inc. | 2 | $50 |
| Verona Pharma, Inc. | 2 | $41 |
| Insmed, Inc. | 2 | $41 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Covis Pharma GmbH | 1 | $15 |
How this compares
$3,228 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 144 | $101,870 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $34,767 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,223 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $4,995 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,241 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,944 |
| Epinephrine | 16 | $3,430 |
| Pulmicort FlexhalerBudesonide | 11 | $2,705 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,002 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,177 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 17 | $860 |
| Doxepin Hcl | 14 | $796 |
| Fluticasone Propionate | 46 | $564 |
| Azithromycin | 55 | $494 |
| Montelukast Sodium | 34 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $966 | $112,093166 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $426 | $41,71378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Sanford
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.